Evaluation of potential chelating agents for radium.
The alpha-particle-emitting radionuclide 223Ra (t(1/2) = 11.4 d) is of interest for use in targeted radionuclide therapy. In order to provide radium-labeled monoclonal antibodies, the development of a chelator binding radium in a stable fashion is required. As a part of the search for potentially useful radium chelators, the relative stability of 223Ra-chelates with linear and cyclic chelating agents was evaluated by means of competition extraction experiments.
Henriksen
Gjermund
G
Department of Chemistry, University of Oslo, Blindern, Norway.
Hoff
Per
P
Larsen
Roy H
RH
D000512:Alpha Particles / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002614:Chelating Agents / Q000737:chemistry / Q000494:pharmacology*; D004355:Drug Stability; D006207:Half-Life; D006801:Humans; D016499:Radioimmunotherapy; D011883:Radium / Q000302:isolation & purification*; D012997:Solvents
D000911:Antibodies, Monoclonal; D002614:Chelating Agents; D012997:Solvents; D011883:Radium